Price Action Report: Zynerba Pharmaceuticals Inc’s Trend Down, Especially After Today’s Weak Session

Price Action Report: Zynerba Pharmaceuticals Inc's Trend Down, Especially After Today's Weak Session

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! The stock decreased 0.54% or $0.07 on November 8, hitting $13.01. About 180,598 shares traded hands. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 19.23% since April 6, 2016 and is uptrending. It has outperformed by 17.28% the S&P500.
The move comes after 5 months negative chart setup for the $128.11 million company. It was reported on Nov, 8 by Barchart.com. We have $11.45 PT which if reached, will make NASDAQ:ZYNE worth $15.37 million less.

Analysts await Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to report earnings on November, 9. They expect $-0.60 EPS, down 3.45% or $0.02 from last year’s $-0.58 per share. After $-0.70 actual EPS reported by Zynerba Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -14.29% EPS growth.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Ratings Coverage

Out of 5 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zynerba Pharmaceuticals has been the topic of 7 analyst reports since August 31, 2015 according to StockzIntelligence Inc. H.C. Wainwright initiated the shares of ZYNE in a report on Friday, October 7 with “Buy” rating. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has “Buy” rating given on Monday, September 14 by Canaccord Genuity. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has “Buy” rating given on Monday, August 31 by Jefferies. Oppenheimer maintained Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) rating on Thursday, November 12. Oppenheimer has “Outperform” rating and $34 price target. The rating was initiated by Piper Jaffray on Monday, August 31 with “Overweight”. Oppenheimer initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) on Tuesday, September 8 with “Outperform” rating.

According to Zacks Investment Research, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.”

ZYNE Company Profile

Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment